Research Analysts’ Weekly Ratings Changes for Harvard Bioscience (HBIO)

A number of firms have modified their ratings and price targets on shares of Harvard Bioscience (NASDAQ: HBIO) recently:

• 3/27/2026 – Harvard Bioscience had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/21/2026 – Harvard Bioscience was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/13/2026 – Harvard Bioscience was given a new $6.00 price target by New Street Research.
• 3/13/2026 – Harvard Bioscience had its price target lowered by Benchmark Co. from $20.00 to $6.00. They now have a “speculative buy” rating on the stock.

Insider Transactions at Harvard Bioscience

In related news, Director Stephen J. Denelsky bought 10,000 shares of the stock in a transaction dated Tuesday, March 17th. The stock was acquired at an average price of $4.87 per share, for a total transaction of $48,700.00. Following the completion of the purchase, the director owned 21,000 shares in the company, valued at $102,270. This represents a 90.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John D. Duke bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were bought at an average price of $5.01 per share, for a total transaction of $25,050.00. Following the completion of the acquisition, the chief executive officer owned 105,000 shares in the company, valued at approximately $526,050. This trade represents a 5.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 36,000 shares of company stock valued at $177,354 over the last quarter. Company insiders own 20.30% of the company’s stock.

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.